Literature DB >> 12821205

Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions.

Courtney L Breen1, Simon J Harris, Nicholas Lintzeris, Richard P Mattick, Lynn Hawken, James Bell, Alison J Ritter, Michael Lenné, Elizabeth Mendoza.   

Abstract

BACKGROUND: Buprenorphine is used in the treatment of opioid dependence. Due to its pharmacology, the transfer from methadone to buprenorphine may precipitate withdrawal symptoms.
METHODS: Methadone maintained patients with clinical indicators of stability who were seeking withdrawal from methadone were recruited from three Australian states. Patients on methadone doses between 30 and 40 mg were randomised to transfer to buprenorphine by a fixed dose (transfer at 30 mg methadone) or by a variable dose induction (transfer when 'uncomfortable'). A third group of patients with methadone doses less than 30 mg were transferred to buprenorphine at their entry methadone dose. Fifty-one patients were inducted onto buprenorphine using the same dosing protocol with the first dose of 4 mg buprenorphine. Following stabilisation on buprenorphine, patients gradually reduced the buprenorphine dose to 0 mg. Withdrawal severity and drug use was monitored.
RESULTS: There were no significant difference between the transfer at 30 mg and transfer when 'uncomfortable' dosing protocols in severity of withdrawal on transfer from methadone to buprenorphine. Those on doses less than 30 mg reported significantly less withdrawal discomfort at transfer. All but one patient stabilised on buprenorphine. Thirty-eight of the 51 patients inducted onto buprenorphine reached 0 mg.
CONCLUSIONS: Transfer from methadone to buprenorphine can safely occur from doses of around 30 mg of methadone. Buprenorphine dose reductions were well tolerated. Thirty-one percent of patients were not using heroin or methadone at 1-month follow-up.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821205     DOI: 10.1016/s0376-8716(03)00071-1

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  11 in total

Review 1.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

2.  Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth.

Authors:  Diane Warden; Geetha A Subramaniam; Thomas Carmody; George E Woody; Abu Minhajuddin; Sabrina A Poole; Jennifer Potter; Marc Fishman; Michael Bogenschutz; Ashwin Patkar; Madhukar H Trivedi
Journal:  Addict Behav       Date:  2012-05-08       Impact factor: 3.913

3.  Increasing diversion of methadone in Vancouver, Canada, 2005-2015.

Authors:  Hudson Reddon; Joel Ho; Kora DeBeck; M-J Milloy; Yang Liu; Huiru Dong; Keith Ahamad; Evan Wood; Thomas Kerr; Kanna Hayashi
Journal:  J Subst Abuse Treat       Date:  2017-11-28

Review 4.  The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.

Authors:  Kelly E Dunn; Stacey C Sigmon; Eric C Strain; Sarah H Heil; Stephen T Higgins
Journal:  Drug Alcohol Depend       Date:  2011-07-08       Impact factor: 4.492

Review 5.  Buprenorphine for managing opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White; Dalitso Mbewe
Journal:  Cochrane Database Syst Rev       Date:  2017-02-21

Review 6.  Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes.

Authors:  Brandon S Bentzley; Kelly S Barth; Sudie E Back; Sarah W Book
Journal:  J Subst Abuse Treat       Date:  2014-12-30

Review 7.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

Review 8.  Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol.

Authors:  David H Epstein; Kenzie L Preston; Donald R Jasinski
Journal:  Biol Psychol       Date:  2006-02-23       Impact factor: 3.251

9.  Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.

Authors:  David Hui; Zoe M Weinstein; Debbie M Cheng; Emily Quinn; Hyunjoong Kim; Colleen Labelle; Jeffrey H Samet
Journal:  J Subst Abuse Treat       Date:  2017-05-16

Review 10.  Pharmacologic treatments for opioid dependence: detoxification and maintenance options.

Authors:  Herbert D Kleber
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.